GE, Vanderbilt team up on immunotherapy AI applications

GE Healthcare and Vanderbilt University Medical Center announced a five-year...Read more on AuntMinnie.comRelated Reading: Bloomberg: GE files papers for healthcare IPO RSNA 2018 Video Roundup: GE Healthcare GE partners with VA Puget Sound on 3D imaging New AI platform, CT scanner pace GE launches at RSNA 2018 GE completes gamma camera recall after detector issue
Source: Headlines - Category: Radiology Source Type: news

Related Links:

It seems that the tipping point has been reached in the Alzheimer's research and development community, in the sense that it is becoming more widely accepted that new approaches are needed. The failure to produce significant benefits to patients via clearance of amyloid from the brain by immunotherapy has spurred a great deal of theorizing, and several new and promising lines of work. For example, working on restoring age-related declines in drainage of cerebrospinal fluid might remove all metabolic waste from the brain. Alternatively, a focus on neuroinflammation and the role of dysfunctional microglia is suggested, parti...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Conclusion: Anti-CV2 autoimmune encephalitis can present as Parkinsonism with bilateral leukoencephalopathy on MRI. PET scanning can be useful to reveal an occult cancer. Treatment of the cancer may improve the paraneoplastic neurological syndrome without the need of immunosuppressive therapy.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsWhile the retrospective nature and small sample size for subgroups are major limitations of this study, these data may indicate that the omission of SRT from first-line treatment may compromise outcome. Pseudoprogression is uncommon with immunotherapy alone; pseudoprogression rates were similar after SRT alone or in combination with immunotherapy or other systemic treatment.Legal entity responsible for the studyUniversity Hospital of Zurich.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsBlood-based detection of ALK fusions results in high ORR and clinical benefit in pts receiving alectinib. These data validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK+ NSCLC.Clinical trial identificationNCT03178552.Editorial acknowledgementMedical Writing support was provided by Nicola Griffin of Gardiner-Caldwell Communications and funded by F. Hoffmann-La Roche.Legal entity responsible for the studyF. Hoffmann-La Roche Ltd.FundingF. Hoffman-La Roche Ltd.DisclosureS.M. Gadgeel: Honoraria (self), Advisory / Consultancy: Ariad, AstraZeneca, Bristol-...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn this analysis, nivo was not associated with HP in the pbo-controlled CheckMate 451 trial. These data are consistent with the previous analysis of ATTRACTION-2, suggesting that reports of HP with immunotherapy may reflect some patients ’ natural course of disease.Clinical trial identificationCheckMate 451 trial: NCT02538666.ONO-4538-12/ATTRACTION-2 trial: NCT02267343.Editorial acknowledgementStephen Gutkin and Jay Rathi, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb.Legal entity responsible for the studyBristol-Myers Squibb and ONO Pharmaceutical Co. Ltd.FundingBristol-Myers Squibb and ONO Phar...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundWith increasing use of immunotherapy and targeted treatments in oncology, it is essential to understand the biological effects of these therapies on tumor kinetics. This retrospective review aims to identify hyperprogressive disease (HPD) occurrence in sarcoma patients treated with immunotherapy or targeted therapy, and its effect on overall survival.MethodsWe performed a retrospective review of advanced sarcoma patients enrolled in immunotherapy or targeted therapy clinical trials at the Princess Margaret Cancer Centre, Toronto. Tumor growth rate (TGR) was assessed for each patient based on serial CT sca...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsImmunotherapy with primary DC subsets induced functional antigen-specific T cells. The presence of functional antigen-specific T cells correlated with longer rPFS.Clinical trial identificationNCT02692976.Legal entity responsible for the studyJolanda de Vries and Winald Gerritsen.FundingThis work was supported by Stichting Afweer Tegen Kanker, Dr. Paul A.J. Speth Stichting and H2020 EU grant PROCROP (grant No 635122). Carl G. Figdor received ERC Adv Grant PATHFINDER (269019) and the NWO Spinoza grant. I. Jolanda M. de Vries received NWO-Vici grant (918.14.655).DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThere are currently no good indicators of which patients with cancer will respond or not to immunotherapy. Novel computational analysis of computed tomography scans (CT) (i.e. radiomics) provides information about the tumour-infiltrating CD8 and predict response to immunotherapy. We aim to validate in an external cohort the VHIO CT-radiomics signature and to develop a combined radiomics-clinical signature that predicts the response to immune checkpoint inhibitors in patients with advanced solid tumours.MethodsThe VHIO CT-radiomics signature was developed in a population of 115 consecutive patients treated...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractHodgkin lymphoma and non-Hodgkin lymphoma are common malignancies in children and are now highly treatable. Imaging plays a major role in diagnosis, staging and response using conventional CT and MRI and metabolic imaging with positron emission tomography (PET)/CT and PET/MRI. Cross-sectional imaging has replaced staging laparotomy and splenectomy by demonstrating abdominal nodal groups and organ involvement. [F-18]2-fluoro-2-deoxyglucose (FDG) PET provides information on bone marrow involvement, and MRI elucidates details of cortical bone and confirmation of bone marrow involvement. The staging system for Hodgkin ...
Source: Pediatric Radiology - Category: Radiology Source Type: research
More News: Immunotherapy | PET Scan | Radiology